Publicacións en colaboración con investigadores/as de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (20)

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

2023

  1. First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

    Journal of Investigational Allergology and Clinical Immunology

  2. Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study

    Chest, Vol. 164, Núm. 4, pp. 837-845

  3. Response to Monoclonal Antibodies in Asthma: Definitions, Potential Reasons for Failure, and Therapeutic Options for Suboptimal Response

    Journal of investigational allergology & clinical immunology, Vol. 33, Núm. 1, pp. 1-13

2022

  1. Early Initiation of Corticosteroids Might be Harmful in Patients Hospitalized With COVID-19 Pneumonia: A Multicenter Propensity Score Analysis

    Archivos de Bronconeumologia, Vol. 58, Núm. 3, pp. 281-283

  2. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

    Chest, Vol. 162, Núm. 4, pp. 768-781

2021

  1. Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 7, pp. 2725-2731

2020

  1. Hospital epidemics tracker (hepitracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers

    JMIR Public Health and Surveillance, Vol. 6, Núm. 3

  2. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab

    Allergy: European Journal of Allergy and Clinical Immunology

2019

  1. A Simple Score for Future Risk Prediction in Patients with Controlled Asthma Who Undergo a Guidelines-Based Step-Down Strategy

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1214-1221.e3

  2. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2

2018

  1. Accuracy of a New Algorithm to Identify Asthma–COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease

    Archivos de Bronconeumologia, Vol. 54, Núm. 4, pp. 198-204

  2. Cardiovascular Studies in Patients with Chronic Obstructive Pulmonary Disease Due to Biomass Smoke or Tobacco

    Lung, Vol. 196, Núm. 2, pp. 195-200

  3. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: A network approach

    International Journal of COPD, Vol. 13, pp. 591-601

  4. The Role of FENO in the Diagnosis and Control of Asthma. Expert Multidisciplinary Group Debate during the Asthma Meeting Point 2017

    Archivos de Bronconeumologia

  5. The post-truth behind the asthma-COPD overlap and the orbit of Mercury: lessons from the CHACOS study

    Archivos de Bronconeumologia, Vol. 54, Núm. 4, pp. 175-176

2017

  1. Asthma-COPD overlap is not a homogeneous disorder: Further supporting data

    Respiratory Research

2016

  1. Asthma, Chronic Obstructive Pulmonay Disease and Other Combinations

    Archivos de Bronconeumologia, Vol. 52, Núm. 10, pp. 499-500

  2. Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients

    Journal of Aerosol Medicine and Pulmonary Drug Delivery, Vol. 29, Núm. 2, pp. 142-152

2012

  1. Omalizumab therapy in severe asthma: Experience from the Spanish registry - Some new approaches

    Journal of Asthma, Vol. 49, Núm. 4, pp. 416-422